BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Cytodyn Inc. CYDY
18 fiscal years on record · USD · FY2024 reported
SEC FILINGS ONLY
EPS · FY24
$0.00
Dividend / sh · FY24
—
Payout · FY24
—
ROE · FY24
—
Net margin · FY24
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2024 · full 18-year series below
Revenue
Net income
Per share
USD 0.00
Diluted EPS, FY2024
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2024
ROE
Operating margin—
Net margin—
Return on assets25.7%
Returned to shareholders
—
returned in FY2024 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
1.25B
Shares outstanding, FY2024
Change, 5 years+140.7%
Change, 10 years—
The share count grew 141% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 18.0M
total assets, end of FY2024
Total assetsUSD 18.0M
EquityUSD -96.0M
CashUSD 11.9M
Gross debtUSD 45.4M
Net debtUSD 33.4M
Current ratio0.25×
Net debt stands at -35% of equity.
History
18 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
Revenue $B
·
·
0.0
0.0
0.0
·
·
·
·
·
·
·
·
·
·
·
·
·
Operating income $B
0.0
−0.0
−0.0
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
·
EBITDA $B
·
−0.0
−0.0
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
·
·
·
Net income $B
0.0
−0.0
−0.1
−0.2
−0.2
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
0.00
−0.05
−0.10
−0.31
−0.30
−0.33
·
·
·
·
·
·
·
·
·
·
·
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
·
·
·
·
·
·
·
·
−566.1
·
·
−672.3
·
·
·
·
·
·
Shares out B
1.25
1.06
0.92
0.72
0.63
0.52
0.33
0.22
0.15
0.12
0.06
0.06
0.03
0.03
0.02
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
36 of 36
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed